Goodness Growth Holdings Subsidiary Resurgent Biosciences Files Patent for Virtual Reality Applications to Facilitate Therapeutic Psychedelic Experiences

Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a physician-led, science-focused cannabis company and IP incubator, today announced that its subsidiary, Resurgent Biosciences ("Resurgent"), has filed for a U.S. patent to create an expansive suite of virtual reality ("VR") applications that can be used by practitioners during psychedelic-based therapies to enhance and guide patients through the experience and potentially create optimized, longer-lasting therapeutic outcomes.

One of the largest unmet needs in the psychedelic space is a scalable platform that will allow medical practitioners to administer psychedelic medicine remotely in a consistent and controlled environment. To address this need, Resurgent is developing a suite of VR applications that will provide customizable environments and programs for psychedelic therapy and the extensive preparation work necessary to optimize therapeutic psychedelic experiences.

"The therapeutic potential of psychedelic medicines at least partially depends on an effective preparation phase to ensure that patients are in the right mindset and in beneficial surroundings in order to create a positive experience, which is often referred to as set and setting," said Chairman and Chief Executive Officer, Kyle Kingsley , M.D. "We believe that VR programs allow practitioners to better prepare and guide patients through their experiences and may optimize therapeutic approaches with psychedelic medicines."

Resurgent has contracted with Cubicle Ninjas, a leading VR development firm in Chicago , to begin work on development of a VR suite for various technology applications for psychedelic therapies. The Cubicle Ninjas team was selected because of their extensive VR development expertise, particularly in the context of health and wellness applications.

Resurgent and Cubicle Ninjas Plan to Begin Developing the Following VR Applications:

  1. A Scalable VR Platform for Use in Psychedelic Medicine, which will provide support for the preparation phase, the peak experience phase, and the post-experience integration phase.
  2. A Psychedelic Biofeedback VR Research Tool, which will focus on providing users simulated psychedelic and other VR experiences coupled with extensive biofeedback data collection with the goal of identifying digital biomarkers that may predict which patients will have the best therapeutic outcomes with psychedelic therapy.
  3. A Group Integration Experience , which will replicate a collective, interactive, group psychedelic experience by harnessing the power of VR to bring remote users into a shared virtual space before, during, and after a peak psychedelic experience.

The applications will allow for practitioners and patients to customize and adapt VR programs based on individual needs with easy-to-use controls and settings. Resurgent expects to have working prototypes completed by the end of the year.

About Goodness Growth Holdings, Inc.

Goodness Growth Holdings, Inc., is a physician-led, science-focused holding company whose mission is to bring the power of plants to the world. The Company's operations consist primarily of its multi-state cannabis company subsidiary, Vireo Health, and its science and intellectual property incubator, Resurgent Biosciences. The Company manufactures proprietary, branded cannabis products in environmentally friendly facilities, state-of-the-art cultivation sites and distributes its products through its growing network of Green Goods™ and other retail locations and third-party dispensaries. Its teams of more than 500 employees are focused on the development of differentiated products, driving scientific innovation of plant-based medicines, and developing meaningful intellectual property. Today, the Company is licensed to grow, process, and/or distribute cannabis in eight markets and operates 17 dispensaries across the United States . For more information about Goodness Growth Holdings, please visit www.goodnessgrowth.com .

About Cubicle Ninjas

Cubicle Ninjas is a creative marketing agency with over 10 years of success creating brands, products, platforms and experiences that drive connections. The full-service creative design agency was founded to create one-of-a-kind experiences through the union of design and technology. Their world-class design and development teams innovate for Fortune 500, start-ups, non-profits, and mid-sized firms alike, crafting functionally intuitive and emotionally impactful work. For more information about Cubicle Ninjas, please visit www.cubicleninjas.com .

Contact Information




Investor Inquiries:

Media Inquiries:

Sam Gibbons

Albe Zakes

Vice President, Investor Relations

Vice President, Corporate Communications

samgibbons@vireohealth.com

albezakes@vireohealth.com

(612) 314-8995

(267) 221-4800

Forward-Looking Statement Disclosure

This press release contains "forward-looking information" within the meaning of applicable United States and Canadian securities legislation. To the extent any forward-looking information in this press release constitutes "financial outlooks" within the meaning of applicable United States or Canadian securities laws, such information is being provided as preliminary financial results and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information contained in this press release may be identified by the use of words such as "plan," "potentially," "potential," "will," "believe,"  "may," "expects,"  or variations of such words and phrases.  These statements should not be read as guarantees of future performance or results. Forward-looking information includes both known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company or its subsidiaries to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements or information contained in this press release. Forward-looking information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of management's experience and perception of trends, current conditions, and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, risks related to current and future economic conditions; risks related to the COVID-19 pandemic; federal, state, local, and foreign government laws, rules, and regulations, including federal and state laws in the United States relating to psychedelics  and any changes to such laws; operational, regulatory, and other risks; execution of business strategy; difficulty to forecast; conflicts of interest; liquidity and additional financing; and risk factors set out in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 , which is available on EDGAR with the U.S. Securities and Exchange Commission and filed with the Canadian securities regulators and available under the Company's profile on SEDAR at www.sedar.com .

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results, or otherwise, other than as required by applicable securities laws.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/goodness-growth-holdings-subsidiary-resurgent-biosciences-files-patent-for-virtual-reality-applications-to-facilitate-therapeutic-psychedelic-experiences-301320653.html

SOURCE Goodness Growth Holdings

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Cannabis leaf.

10 Biggest Cannabis Stocks in the US and Canada in 2026

After a year of stop‑start policy signals, the US cannabis market ended 2025 with a new wave of attention as US President Donald Trump moved to accelerate federal cannabis rescheduling efforts. His December executive order directing the attorney general to complete the process of shifting... Keep Reading...
Cannabis business with marijuana leaves and stock

Cannabis Market 2025 Year-End Review

2025 marked a turning point for investment in the cannabis sector, shifting the focus toward operational resilience and consolidation after a sluggish 2024. Key market drivers included an upswing in merger and acquisition (M&A) activity as stronger multi-state operators (MSOs) acquired... Keep Reading...
Cannabis plant with green leaves and buds on a dark green background.

Cannabis Market Forecast: Top Trends for Cannabis in 2026

The US cannabis market is entering 2026 with brighter prospects after a punishing few years marked by stalled rescheduling efforts, price compression, retail saturation and slow state expansion.Now, however, regulatory tailwinds seeming aligned for a potential re-rating.On December 18, US... Keep Reading...
Cannabis plant in focus, blurred US flag background.

Analysts React: Trump Signs Executive Order to Reschedule Cannabis

The long-debated issue of US cannabis rescheduling is finally back in the spotlight. On Thursday (December 18), President Donald Trump signed an executive order to expedite the process of moving cannabis from Schedule I to Schedule III under the Controlled Substances Act. Market watchers are now... Keep Reading...
Close-up of green cannabis leaves in natural light.

Trump Weighs Executive Order to Loosen Federal Cannabis Restrictions

US President Donald Trump is reportedly weighing a major shift in federal drug policy that would relax decades-old restrictions on cannabis, potentially injecting new life into the industry. Six people familiar with the discussions told the Washington Post that Trump is preparing an executive... Keep Reading...
Gavel on a surface with scattered cannabis leaves, symbolizing legal issues around marijuana.

Hemp THC Recriminalization: A Blow to a Blooming Industry

A spending bill to reopen the US government after a 43 day shutdown includes provisions that will recriminalize most hemp-derived THC products. This change, slated to become effective one year after enactment, in late 2026, marks a significant policy reversal from the 2018 Farm Bill, which... Keep Reading...

Interactive Chart

Latest Press Releases

Related News